Skip to main content

Please wait while loading...


Who We Are

PPI was established to share data and insights that inform public policy and shape the healthcare programs of the future. We strive to be an objective and credible contributor to healthcare transformation through the publication of policy-relevant data analysis, timely research, and insights from the innovative programs of Elevance Health's affiliated health plans.

Our Focus

PPI conducts health policy research and data analysis, and produces papers, issue briefs, and other materials, to contribute thought leadership to the policy discourse. We also share policy-relevant insights garnered from the innovative programs of Elevance Health’s affiliated health plans.

PPI convenes and connects with experts and thought leaders to share information, hold discussions, and debate solutions relevant to healthcare and health policy. We support external research that informs public policy and adds to the collective body of knowledge by using publicly and privately available data sources to answer timely questions.

PPI is comprised of an expert team of health policy analysts with experience working on behalf of or as part of government agencies, payers, providers, and life sciences companies. The team brings extensive knowledge of federal and state health policy and regulation as well as qualitative and quantitative research methods.

Areas of Research Interest

PPI’s work aligns with areas of interest to federal and state policymakers, employers, consumers, researchers, and other stakeholders, including issues relevant to Medicare, Medicaid, and commercial health insurance. We also support the advancement of critical areas of focus in health policy, including consumer engagement, access, affordability and the cost of healthcare, quality of care, prescription drugs, social drivers of health, disability and aging, digital healthcare, and the transformation of healthcare delivery.

Our work includes evaluating the impact on health outcomes and healthcare utilization from changes to managed care delivery, such as the investment in services to address health-related social needs or plan benefit designs that are tailored for better management of chronic conditions.

We also invest in research and analysis to understand the implications of policy proposals and enacted policy changes, such as states’ approaches to delivering certain Medicaid benefits or changes to risk adjustment in the Medicare Advantage program.

Finally, PPI partners with academic institutions to support empirical analyses that can inform future policy development and delivery system reform, such as understanding the market dynamics influencing prescription drug competition and prices. 

Our Partners

In pursuit of our objective to shape healthcare policy through the creation and dissemination of credible, relevant research, PPI has partnered with these organizations:

Brigham and Women’s Hospital

PPI is funding new research and data analysis on prescription drug market dynamics, competition, and prices. The work investigates the impact of interclass competition on branded drug prices, factors affecting generic drug uptake, and use and impact on spending of authorized generics.

The George Washington University Milken Institute School of Public Health

PPI sponsored research and analysis on the applicability of the False Claims Act (FCA) to the Medicare Advantage (MA) program. The work compared the role of the FCA in MA and the traditional Medicare fee-for-service (FFS) system, highlighting unique challenges and misalignments underlying FCA enforcement in MA.

Harvard Medical School

PPI is a sponsor of the Healthcare Markets and Regulation (HMR) Lab of the Department of Health Care Policy at Harvard Medical School, and member of the HMR Lab’s Industry Working Group. In addition, PPI funded research that examined risk selection and the effectiveness of risk mitigation programs in the individual health insurance market.

Penn Medicine

In partnership with CareMore Health, PPI sponsored research on high-cost, high-need individuals enrolled in Medicare Advantage (MA) plans. Additional research evaluated the impact of MA Special Needs Plan (SNP) enrollment among individuals with end-stage renal disease (ESRD).